{"id":"W2605003339","doi":"10.1016/j.pupt.2017.03.017","title":"Response to the article “Sorafenib as a potential strategy for refractory pulmonary arterial hypertension”","year":2017,"lang":"en","type":"letter","venue":"Pulmonary Pharmacology & Therapeutics","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Sunitinib; Medicine; Sorafenib; Refractory (planetary science); Internal medicine; Toxicity; Dosing; Progressive disease; Retrospective cohort study; Progression-free survival; Oncology; Renal cell carcinoma; Surgery; Urology; Overall survival; Disease; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001603716,0.0008772588,0.001777117,0.0007912201,0.002621912,0.003149658,0.001686568,0.04151503,0.005776786],"category_scores_gemma":[0.01816186,0.000561142,0.00140479,0.0006837858,0.002032846,0.002370891,0.001127583,0.03385311,0.005133107],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003548732,"about_ca_system_score_gemma":0.002788085,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002303248,"about_ca_topic_score_gemma":0.003773638,"domain_scores_codex":[0.9981483,0.0005665539,0.0002056295,0.0002268673,0.0004805147,0.0003721786],"domain_scores_gemma":[0.9963405,0.00190293,0.0003436061,0.00009665918,0.0006210545,0.0006952184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002457185,0.0001224214,0.001069496,0.0001136601,0.00004135966,0.01352449,0.0001336469,0.0002941917,0.0003630895,0.002431488,0.9695532,0.0121074],"study_design_scores_gemma":[0.0007511676,0.0005450537,0.002876937,0.0006626825,0.00015287,0.01816013,0.0008148025,0.003447777,0.001023277,0.01484833,0.956534,0.0001829935],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0008480918,0.001123176,0.0001579431,0.9742869,0.02138847,0.00002913884,0.00007925867,0.00005015729,0.002036935],"genre_scores_gemma":[0.007213837,0.001215504,0.0003018438,0.933407,0.05304689,0.00005414239,0.00006930347,0.00002944137,0.00466201],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.04151503,"threshold_uncertainty_score":0.02574795,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07495197995845619,"score_gpt":0.3657364348723154,"score_spread":0.2907844549138592,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}